SARS-CoV-2 3CLpro-IN-5

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro) . SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA) . SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) [1].

Product Specifications

CAS Number

[2913186-57-7]

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sars-cov-2-3clpro-in-5.html

Solubility

10 mM in DMSO

Smiles

FC1=CC=CC2=C1C=C(C(N[C@H](C(NN(C([C@@](F)([H])Cl)=O)C[C@H]3C(NCC3)=O)=O)CC(C)C)=O)N2

Molecular Formula

C22H26ClF2N5O4

Molecular Weight

497.92

References & Citations

[1]Yuya Hirose, et al. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. J Med Chem